Safety and Effectiveness of CD4-IgG2 in HIV-Positive Children
HIV Infections

About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Antiviral Agents, CD4-IgG(2), PRO 542
Eligibility Criteria
Inclusion Criteria Children may be eligible for this study if they: Are HIV-positive. Are 2-12 years old and have consent of parent or legal guardian. Have HIV levels of 10,000 copies/ml or more on at least 2 occasions and 30 days apart (Part 2 only). Have been on stable, unchanged anti-HIV therapy for 3 months before study entry. Exclusion Criteria Children will not be eligible for this study if they: Have an active opportunistic (HIV-related) infection. Are pregnant. Are taking certain medications. Have received any vaccinations within 30 days prior to study entry. Have a heart problem that would affect their ability to take part in the study. (This study has been changed. The original version didn't mention heart problems.)
Sites / Locations
- Long Beach Memorial Med. Ctr., Miller Children's Hosp.
- Childrens Hosp. LA - Dept. of Ped., Div. of Clinical Immunology & Allergy
- UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS
- Children's Hosp. of Orange County
- UCSF Pediatric AIDS CRS
- Children's National Med. Ctr. Washington DC NICHD CRS
- Univ. of Florida Jacksonville NICHD CRS
- Texas Children's Hosp. CRS